Every 8-K that Senseonics (SENS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SENS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SENS filings page.
Senseonics Holdings, Inc. reported record results for the quarter ended June 30, 2026, with total revenue of $14.5 million, an increase of approximately 120% from $6.6 million a year earlier. U.S. revenue rose to $12.6 million, while revenue outside the U.S. was $1.9 million, reflecting the integration of European commercial operations and growth in the Eon Care program.
Gross profit was $8.6 million, for gross margin of approximately 59%, up from 47% in the prior-year quarter. Higher investment in the Gemini and Freedom development programs and commercial integration drove research and development expenses to $11.6 million and selling, general and administrative expenses to $32.9 million, resulting in a net loss of $36.7 million, or $0.63 per share. As of June 30, 2026, cash, restricted cash and cash equivalents totaled $143.0 million and outstanding indebtedness was $55.5 million. Senseonics raised its full-year 2026 revenue guidance to $62–$66 million and gross margin guidance to 58%–61%, citing commercial momentum and the global roll-out of Eversense 365.
Senseonics Holdings, Inc. has completed the previously announced local asset purchase agreements with Ascensia Diabetes Care for its commercial Eversense continuous glucose monitoring (CGM) activities in several European markets. These transactions cover Eversense CGM commercial assets in Germany, Spain, Sweden and Italy.
The asset purchases in Germany, Spain and Sweden closed on June 1, 2026, and the purchase related to Italy closed on June 8, 2026, with the transfer effective for finance and accounting purposes as of June 1, 2026. This shifts ownership of these commercial assets from Ascensia to Senseonics and its affiliates in the covered countries.
Senseonics Holdings, Inc. held its 2026 annual meeting, where stockholders approved doubling the authorized common stock from 70,000,000 to 140,000,000 shares through a charter amendment effective May 20, 2026. Stockholders also elected three directors, approved executive pay on an advisory basis, and chose to hold say‑on‑pay votes annually.
They ratified KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026, approved the charter amendment increasing authorized shares, and adopted the Senseonics Holdings, Inc. 2026 Equity Incentive Plan. At the meeting, 23,650,239 shares, or 56.59% of the 41,795,466 shares outstanding as of the record date, were present or represented by proxy.
Senseonics Holdings, Inc. reported first quarter 2026 revenue of $11.7 million, up from $6.3 million a year earlier, reflecting 87% growth driven mainly by U.S. sales of the Eversense continuous glucose monitoring systems. U.S. revenue was $9.3 million, while revenue outside the U.S. was $2.4 million.
Gross profit rose to $6.9 million from $1.5 million, but higher operating spending linked to bringing Eversense commercialization in-house pushed the net loss to $32.3 million, or $0.71 per share, compared with a $14.3 million loss, or $0.40 per share, in the prior-year quarter.
Cash, cash equivalents and investments totaled $64.6 million with indebtedness of $35.2 million, after securing over $100 million in equity and debt financing. For full-year 2026, the company now expects global net revenue of $60–$64 million, representing 70%–82% growth, and gross margins of 55%–58%.
Senseonics Holdings, Inc. amended its existing term loan facility with Hercules Capital, expanding access to up to $140.0 million in senior secured term loans. The structure now includes a previously funded $35.0 million initial loan, a $10.0 million Tranche 2 loan and a $10.0 million Tranche 3A loan that the company expects to be funded at the Second Amendment closing on May 6, 2026, plus additional future tranches subject to milestones.
The loans bear interest at the greater of the prime rate plus 2.40% or 9.90% annually and mature on September 3, 2029, with an interest-only period potentially lasting until maturity if a specified 2025 milestone is met. Senseonics will pay a $100,000 facility fee, a $100,000 amendment fee, tiered prepayment penalties, and extra facility fees on later tranches.
In connection with each funded tranche, the company will issue additional stock purchase warrants exercisable for a number of common shares equal to 2.0% of the funded loan amount divided by the three-day volume-weighted average share price, adding potential future equity dilution alongside increased debt capacity.
Senseonics Holdings, Inc. entered an underwriting agreement to sell 8,000,000 shares of common stock and 8,000,000 pre-funded warrants at $5.00 per share or $4.999 per warrant, for expected net proceeds of about $74.7 million, or $86.0 million if underwriters fully exercise a 2,400,000-share option.
For the quarter ended March 31, 2026, the company preliminarily expects revenue of approximately $11.7 million, gross profit of about $6.4 million with a gross margin near 54%, and a net loss between $31 million and $33 million, with cash and equivalents around $64.6 million and stockholders’ equity between $33.7 million and $35.7 million.
Through a non-binding term sheet with Hercules Capital, Senseonics proposes to expand its Loan and Security Agreement capacity from $100.0 million to $140.0 million, including $20.0 million of near-term commitments and up to $85.0 million in additional future tranches, which would have resulted in about $55.0 million of total debt outstanding as of December 31, 2025 on an as-adjusted basis.
Senseonics Holdings, Inc. has entered into a series of Local Asset Purchase Agreements with Ascensia Diabetes Care to acquire additional assets tied to commercial Eversense CGM activities in Italy, Germany, Spain and Sweden. These European Asset Purchases build on a prior master asset purchase agreement covering U.S. rights.
At each European closing, expected on or before June 30, 2026 subject to customary conditions and required consents, Senseonics will pay cash based on the net book value of the related assets and assumed liabilities. A separate Transition Services Agreement will have Ascensia provide logistics, IT, finance, regulatory and other support in the European territories, generally through dates up to June 30, 2026, to help ensure an orderly handover and continuity of Eversense operations.
Senseonics Holdings, Inc. reported strong growth for the fourth quarter and full year 2025 while continuing to invest heavily in commercialization of its Eversense 365 long-term CGM system. Q4 revenue rose to $14.3 million, up from $8.3 million, driven mainly by U.S. sales.
For 2025, total revenue increased to $35.3 million from $22.5 million, and gross profit improved sharply to $15.8 million from $0.5 million as one-time transition charges rolled off and margins on the 365-day product improved. The annual net loss narrowed to $69.1 million, or $1.66 per share, from $78.6 million, reflecting better gross profit offset by higher selling, general and administrative expenses as the company took Eversense commercialization and distribution back in-house and ramped direct-to-consumer marketing.
Cash, cash equivalents and investments totaled $94.3 million with indebtedness of $35.3 million at December 31, 2025. For 2026, Senseonics expects global net revenue of $58–$62 million, implying 65–76% growth, and targets gross margins of about 50% as it completes the transition from Ascensia and expands Eversense 365 globally and into automated insulin delivery integrations.
Senseonics Holdings, Inc. furnished a current report to share business updates and preliminary, unaudited financial information for the year ended December 31, 2025. The company did this by issuing a press release, which is attached as Exhibit 99.1, and referenced in the report for details on preliminary revenue and year-end cash, cash equivalents and restricted cash levels.
The company notes that these figures are estimates, have not been reviewed or audited, and may change when its 2025 financial statements are finalized and audited. The report emphasizes that statements about expected fourth quarter 2025 and full-year 2025 results are forward-looking and subject to risks described in prior annual and quarterly reports.
Senseonics Holdings, Inc. reported that it issued a press release announcing financial results for the quarter ended September 30, 2025, and provided details for a conference call to discuss results, corporate highlights, and outlook. The press release was furnished as Exhibit 99.1 to this report. The information in this report, including Exhibit 99.1, is being furnished and shall not be deemed filed under the Exchange Act.
Senseonics Holdings (SENS) approved a 1-for-20 reverse stock split and reduced authorized common shares to 70,000,000. The action is set by a Certificate of Amendment and becomes effective at 4:05 p.m. Eastern Time on October 17, 2025. At the effective time, every twenty issued and outstanding common shares will be combined into one share, with no change to par value.
The split triggers proportional adjustments to outstanding stock options, restricted stock units, warrants, and the share reserves under equity plans. Fractional shares will not be issued; stockholders otherwise entitled to a fraction will receive a cash payment instead. The reverse split applies to all holders proportionately and does not change any holder’s ownership percentage, aside from effects related to fractional shares. The common stock is expected to begin trading on a split-adjusted basis on the NYSE American on October 20, 2025 under the symbol SENS.
Senseonics Holdings, Inc. reported preliminary, unaudited revenue of approximately $8.1 million for the third quarter of 2025. This represents a 91% increase compared to the third quarter of 2024, primarily driven by approximately 160% growth in new U.S. patients over the prior year period.
The company emphasized that these figures are preliminary estimates based on information currently available, have not been reviewed or audited by its independent registered public accounting firm, and may change when full third quarter 2025 financial statements are finalized and reviewed.
Senseonics Holdings, Inc. furnished an update on its business and finances by attaching a press release that includes preliminary, unaudited financial information for the quarter ended September 30, 2025. The company provided this update under the "Results of Operations and Financial Condition" section, indicating it covers recent operating performance and balance sheet trends. The press release, dated October 6, 2025, is included as Exhibit 99.1, while the cover page Inline XBRL data is included as Exhibit 104. The company emphasized that this information is being furnished rather than filed, which limits certain legal liabilities under the securities laws.
Senseonics Holdings, Inc. reported that its stockholders approved a proposal at a special meeting to allow the Board of Directors to implement a reverse stock split of the Company’s common stock. The approved amendments to the Amended and Restated Certificate of Incorporation permit a reverse split in a range from 1-for-10 to 1-for-20, with a proportionate reduction in the authorized number of shares of common stock, at any time prior to September 29, 2026, as determined by the Board in its sole discretion.
The proposal passed with 285,639,190 votes for, 178,232,358 votes against, and 5,014,498 abstentions, showing substantial but not unanimous support. This approval gives the Board flexibility to adjust the share count and share price structure in the future within the approved range.
Senseonics Holdings, Inc. (NYSE American: SENS) filed a Form 8-K dated August 6, 2025 under Item 2.02 to furnish a press release (Exhibit 99.1) announcing its results for the quarter ended June 30, 2025. The press release also provides details for an accompanying conference call covering recent corporate highlights and the Company’s outlook. In accordance with SEC rules, the furnished material is not deemed “filed” for liability purposes and will not be incorporated by reference into other SEC filings. No quantitative financial data, guidance figures, or strategic updates are included in the 8-K itself.